BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 29618650)

  • 1. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
    Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
    Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
    Baig TT; Feng Y; Chelico L
    J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
    Yu Q; Chen D; König R; Mariani R; Unutmaz D; Landau NR
    J Biol Chem; 2004 Dec; 279(51):53379-86. PubMed ID: 15466872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and Structural Insights into a Vif/PPP2R5 Complex Elucidated Using Patient HIV-1 Isolates and Computational Modeling.
    Salamango DJ; McCann JL; Demir Ö; Becker JT; Wang J; Lingappa JR; Temiz NA; Brown WL; Amaro RE; Harris RS
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32847850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
    Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
    J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
    Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
    J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
    Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
    J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.
    Nagao T; Yamashita T; Miyake A; Uchiyama T; Nomaguchi M; Adachi A
    J Med Invest; 2010 Feb; 57(1-2):89-94. PubMed ID: 20299747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
    Yoshikawa R; Izumi T; Yamada E; Nakano Y; Misawa N; Ren F; Carpenter MA; Ikeda T; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
    J Virol; 2016 Jan; 90(1):474-85. PubMed ID: 26491161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
    De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
    AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
    Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
    J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner.
    Bandarra S; Miyagi E; Ribeiro AC; Gonçalves J; Strebel K; Barahona I
    J Virol; 2021 Nov; 95(23):e0117021. PubMed ID: 34523960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.
    Chesarino NM; Emerman M
    J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.